New guidelines on abiraterone

User

Posted 16 Jan 2026 at 19:20

Great news that this drug has now been approved to give to men in England . It’s been available in Scotland and wales for a while . My husband Gary was lucky enough to be on the stampede trial . He’s still here 10 yrs later ,after being diagnosed at 55 psa 23 4+5 Gleason ,spread to para aorta nodes .Still working and psa undetectable . To all you gents on this journey, have hope . At the start of his journey we had no grandchildren,now we’re about to have out 8th !
best wishes to you all .

Debby xx

User

Posted 16 Jan 2026 at 19:20

Debby xx

User

Posted 17 Jan 2026 at 00:26

It will be interesting to see the exact wording of the document and the criteria for eligibility. When I was trying to get it, spread to multiple lymph nodes only, was not considered to be metastatic. I was put on the far more expensive apalutamide. It does sound as if there has been a change to that criteria.

Thanks Chris

Show Most Thanked Posts

User

Posted 17 Jan 2026 at 00:26

Thanks Chris

User

Posted 19 Jan 2026 at 19:42

Hi Chris,
that’s great news.
was it his first course of treatment?

I’ve had SRT after a prostatecomy and have asked for it as a preventative measure but have been told it wouldn’t help.

any ideas?

regards

Mark

User

Posted 19 Jan 2026 at 22:57

Marky, similar to your self, surgery, salvage RT, two lot's of SABR treatment to pelvic lymph nodes. Started HT about 9 months ago.

Thanks Chris

User

Posted 20 Jan 2026 at 23:58

Originally Posted by: Online Community Member

Thanks Chris

Inclusion criteria here published by NHS England a few days ago.

Inclusion criteria
All patients with newly diagnosed high-risk, hormone sensitive prostate cancer or relapsing
prostate cancer with high-risk features planned for standard of care treatment with
radiotherapy (unless contraindicated) who meet the following eligibility criteria.
3 The evidence informing the development of this policy comes from a clinical trial where patients were
staged according to images obtained from CT, MRI and bone scans.
4
Newly diagnosed high-risk prostate cancer
Eligible patients are defined as:
• WHO performance status 0-2
AND
• Non-metastatic (M0)
AND EITHER
• Pelvic node positive (N1)
OR
• Node negative (N0) with at least two of:
o tumour stage T3 or T4
o Gleason score 8-10
o Prostate specific antigen (PSA) ≥ 40 nanograms/ml
Relapsing prostate cancer with high-risk features
Eligible patients are defined as previously radically treated prostate cancer with an interval
of ≥12 months without treatment and:
• WHO performance status 0-2
AND
• Non-metastatic (M0)
AND EITHER
• Pelvic node positive (N1)
OR
• Node negative (N0) with one of either:
o a PSA concentration ≥4 nanograms/ml with a doubling time of <6 months
o a PSA concentration ≥20 nanograms/ml).
excludes those with contraindications to abiraterone and "clinically significant cardiovascular disease".
The WHO performance status 0-2 is about being physically able to look after yourself not confined to chair or bed most of the time.
ADT must start first and then Abiraterone and prednisolone should be taken for 2 years.

https://www.england.nhs.uk/wp-content/uploads/2026/01/2312-clinical-commissioning-policy-abiraterone-acetate-and-prednisolone-for-high-risk-hormone-sensitive-non-metastatic-prostate-cancer-adults.pdf

Edited by member 21 Jan 2026 at 00:00 | Reason: Not specified

Notification

Join the online community now.